CytoSorbents Maintains Rating and Price Target with D. Boral Capital Reaffirmation

CytoSorbents (CTSO) maintains a "Buy" rating and $10.00 price target by D. Boral Capital. Analyst Jason Kolbert reiterates the positive outlook. The average one-year price target is $5.00, with a high estimate of $10.00 and a low estimate of $1.00, indicating an upside of 316.67% from the current price of $1.20. The consensus recommendation is 2.5, indicating "Outperform" status. The estimated GF Value in one year is $1.42, suggesting a 18.33% upside from the current price.

Title: Analysts Maintain Bullish Outlook on CytoSorbents (CTSO); FDA Appeal for DrugSorb-ATR Device

CytoSorbents (CTSO) has received a mix of bullish and bearish analyst ratings in recent months, with a notable positive outlook from D. Boral Capital. The firm maintains a "Buy" rating and a $10.00 price target, reiterated by analyst Jason Kolbert. This positive sentiment is reflected in the average one-year price target of $5.00, with a high estimate of $10.00 and a low estimate of $1.00, indicating an upside potential of 316.67% from the current price of $1.20. The consensus recommendation is 2.5, indicating an "Outperform" status. The estimated GF Value in one year is $1.42, suggesting an 18.33% upside from the current price.

Analyst Sentiment

Analysts have provided a range of ratings for CytoSorbents over the past three months. D. Boral Capital, one of the prominent firms, has maintained a "Buy" rating with a price target of $10.00, reflecting a bullish stance on the company's prospects. Jason Kolbert, an analyst at D. Boral Capital, has reiterated this positive outlook, emphasizing the company's potential for growth. Despite the mixed sentiment from other analysts, the overall consensus remains bullish, with an average target price of $7.00 and a high estimate of $10.00.

FDA Appeal for DrugSorb-ATR

CytoSorbents has filed a request for supervisory review with the U.S. Food and Drug Administration (FDA) for its DrugSorb-ATR device. The device, which received Breakthrough Device Designation, aims to reduce bleeding in patients undergoing coronary artery bypass grafting (CABG) surgery. The FDA's denial letter highlighted unresolved issues that must be addressed before the De Novo request can be approved. CytoSorbents is engaging with the FDA to clarify and resolve these issues through a supervisory review process, which typically involves a formal hearing and a final decision within approximately 60 days.

Financial Insights

CytoSorbents' market capitalization remains above industry averages, reflecting its strong market presence. However, the company has faced challenges in revenue growth, with a decline of approximately -2.92% over the past three months. Despite this, the company's net margin and return on equity (ROE) are impressive, surpassing industry averages. The debt-to-equity ratio is 1.85, indicating a substantial amount of debt, which could pose financial challenges.

Conclusion

CytoSorbents continues to attract a mix of analyst ratings, with a notable positive outlook from D. Boral Capital. The company's appeal to the FDA for the DrugSorb-ATR device highlights its commitment to resolving regulatory issues and advancing its product portfolio. While financial challenges persist, the company's strong profitability and efficient use of capital offer a positive outlook for investors.

References

[1] https://www.nasdaq.com/articles/deep-dive-cytosorbents-stock-analyst-perspectives-6-ratings
[2] https://www.marketscreener.com/quote/stock/CYTOSORBENTS-CORPORATION-19475884/news/Cytosorbents-Corporation-Files-Appeal-with-U-S-Fda-for-Supervisory-Review-of-Its-De-Novo-Request-fo-50321368/
[3] https://www.gurufocus.com/news/2941628/cytosorbents-ctso-seeks-fda-review-for-drugsorbatr-approval-ctso-stock-news